Pediatric Drugs and Vaccines: A Global Strategic Business Report
San Jose, CA (Vocus/PRWEB) April 15, 2011
For several years, physicians were paralyzed with lack of information and options for prescribing treatment to patients in the pediatrics market. Many were compelled to rely on off-label prescription of drugs, as the market was deprived of approved drugs in many segments. This also created a fret among physicians and pediatricians pertaining to the safety and efficacy of these drugs. Yet another issue that raised the bar of unmet needs and dearth in drugs for pediatric patients is the rising incidence and prevalence of metabolic conditions, CNS, and cardiovascular diseases among pediatric patients. Pediatric drugs market, traditionally the most undervalued and underserved segment in the global pharmaceutical market, is emerging as an area of opportunity for pharmaceutical companies. Pediatric drugs is emerging as an area of hope and prosperity, as the global pharmaceutical industry ventures into an period of uncertainty dotted with significant losses in terms of patent expiration of several market leading drugs, narrowing drug pipeline, generic onslaught and increasing focus of companies on optimization of portfolios. Growth is primarily expected to emanate from pediatric vaccines and hormone therapy drugs as well as from respiratory and allergy drugs, CNS drugs, and anti-infectives. Revenues in the pediatric drugs market are likely to surge in the following years, owing to new approvals of numerous existing products, as well as launch of new products mainly targeted at children.
Several regulations such as Best Pharmaceuticals for Children Act (BPCA), Pediatric Drug Research Equity Act (PREA), Food & Drug Administration Modernization Act (FDAMA), have been set up for rectifying flaws in the pediatric drugs market. Moreover, to encourage drug manufacturers for performing clinical trials for the pediatric population, the FDA and EMA have adopted new regulations. Several other factors are also driving growth of the pediatric drugs, and the industry is expected to be one of the fastest growing drug markets in the coming decade. The pediatric exclusivity program initiated in the US bore significant fruits, with several studies suggesting that the initiative has resulted in economic benefits to drug companies as well as improved patient care through availability of drugs for this patient population. Over the years, the initiative remained the key driver for encouraging pharmaceutical companies to research on pediatric use of existing drugs. Going forwards, both the factors, generating incremental revenue from pediatric exclusivities and new revenue source by developing new drugs, are expected to play an instrumental role in driving the interests of pharmaceutical companies in the pediatric drugs market.
The US represents the largest regional market for pediatric drugs and vaccines globally, as stated by the new market research report on Pediatric Drugs and Vaccines. Europe trails behind the US market. However, growth in the market would be led by Asia-Pacific, which is projected to be the fastest growing regional market, and is forecast to witness a CAGR of more than 11% during the analysis period. Anti-infective Drugs represents the largest segment, while Pediatric Vaccines represents the fastest growing segment in the global pediatric drugs and vaccines market. Global market for Pediatric Hormones is forecast to grow at a CAGR of 7.0% during the analysis period.
Several innovative drug-delivery technologies are under development for facilitating easy administration of pediatric drugs, as taste and texture are major issues witnessed in consumption of medicines by children. Moreover, to minimize use of injections in children, various other needle-free, non-invasive alternatives such as inhalable formulations, thin-strip technologies, and transdermal patches, are prevalent.
Major players profiled in the report include Abbott Laboratories, Allergan Inc., AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Merck Serono, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi-Aventis, UCB Pharma, among others.
The research report titled “Pediatric Drugs and Vaccines: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the pediatric drugs and vaccines markets, current market trends, key growth drivers, overview of diseases in children, the prevalence, the treatment, insight into pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for pediatric drugs and vaccines market for years 2009 through 2017 for the following geographic markets - US, Europe, Asia-Pacific, Latin America, and Rest of World. The report analyses the market for pediatric drugs and vaccines market by the following segments – Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Pediatric_Drugs_and_Vaccines_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/